HER2 Breast Cancer

Pyrotinib combined with apecitabine demonstrated promising activity in patients with HER2-positive breast cancer that have brain metastases, according to findings from the prospective phase 2 PERMEATE study.

Significant survival improvement has been shown with trastuzumab deruxtecan in patients with HER2-low breast cancer treated in the DESTINY-Breast04 clinical trial.

Andrew Seidman, MD, discusses the FeDeriCa trial of intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the KAMILLA trial and the benefit of trastuzumab emtansine.

In an interview with Targeted Oncology, Ron Bose, MD, MPH, discussed HER2 drug resistance, its impact on treatment, and how new research may help in the future.

The FDA has accepted a supplement biologics license application for fam-trastuzumab deruxtecan-nxki and granted it priority review for the treatment of adult patients with unresectable or HER2-positive metastatic breast cancer who have received a prior anti-HER2- based regimen.

Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

HER2 mutations are a major clinical biomarker in breast cancer. However, overcoming drug resistance remains a key clinical obstacle.

Based on updated findings from the phase 2 SUMMIT trial, a neratinib triplet and neratinib doublet can induce responses in patients with HER2-positive breast cancer.

Fam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.

Updated data from the PHOEBE trial show that pyrotinib plus capecitabine improved overall survival in patients with HER2-positive breast cancer compared with lapatinib plus capecitabine.

Adding zanidatamab to chemotherapy may result in positive efficacy and safety outcomes in patients with HER2-positive breast cancer.

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.

In an interview with Targeted Oncology, lead author Xichun Hu, MD, PhD, discussed A166 and its impact on HER2-positive breast cancer.

Frederick Howard, MD, a medical oncology fellow in the Department of Medicine at the University of Chicago, discussed the clinical benefits of the SimBioSys TumorScope model for the treatment of early breast cancer in an interview with Targeted Oncology.

Zanidatamab in combination with evorpacept has been dosed for the first time in a patient with HER2-low breast cancer.

Based on results from the DESTINY-Breast03 clinical trial, trastuzumab deruxtecan has been granted another breakthrough therapy designation by the FDA.

When comparing de-escalated neoadjuvant ado-trastuzumab emtansine, with or without endocrine therapy, vs trastuzumab plus endocrine therapy baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-positive early stage breast cancer.

Progression-free survival after [vic]-trastuzumab duocarmazine treatment in patients with pretreated, metastatic HER2-positive breast cancer was improved compared with physician’s choice chemotherapy.

Patients with previously treated HER2-positive metastatic breast cancer experienced a clinically meaningful and statistically significant improvement in progression-free survival with fam-trastuzumab deruxtecan-nxki vs standard of care trastuzumab emtansine in the DESTINY-Breast03 trial.

Erica Stringer-Reasor, MD discusses the results of a phase 2 study examining the combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive breast cancer with leptomeningeal metastasis.

In an Interview with Targeted Oncology, Debasish Tripathy, MD, discusses the triplet regimen for HER2+ breast cancer with leptomeningeal metastases in greater detail along with its broader clinical applications.

In an interview with Targeted Oncology™, lead study author Elisa Agostinetto, MD, of the Istituto Clinico Humanitas in Rozzano, Milan, Italy, discussed the accuracy of PREDICT+ in HER2-positive breast cancer in greater detail and its clinical implications.

In an interview with Targeted Oncology™, Erica Stringer-Reasor, MD, discusses the study in more detail and how this newly approved triplet combination may improve survival for patients living with HER2-positive breast cancer with central nervous system metastases.